期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

B细胞靶向治疗在系统性红斑狼疮的应用 被引量：1

下载PDF
导出
摘要 B细胞被认为是在系统性红斑狼疮(SLE)发病学中的一个重要因素,因此也成为SLE治疗的一个焦点。本文针对B细胞靶向治疗的不同方法,如B细胞清除、阻断联合刺激信号、B细胞耐受、抗细胞因子等做一简要综述。
作者 李坤鹏 张江林
机构地区 解放军总医院风湿科
出处 《军医进修学院学报》 CAS 2009年第1期35-36,共2页 Academic Journal of Pla Postgraduate Medical School
关键词 红斑狼疮 系统性 B淋巴细胞 毒素类 靶向 治疗
分类号 R593.24 [医药卫生—内科学]
  • 相关文献

参考文献14

  • 1Kalunian K, Davis JC, Merrill JT, et al. IDEC-131 Lupus Study Group. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with antiCD154: a randomized, double-blind,placebo-controlled trial [ J ]. Arthritis Rheum, 2002, 46 : 3251- 3258.
  • 2Boumpas D, Furie R, Manzi S, et al. BG9588 Lupus Nephritis Trial Group. A short course of BG9588 ( anti-CD40 ligand anti- body) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis [ J ]. Arthritis Rheum, 2003, 48:719-727.
  • 3Nitschke L, Carsetti R, Ocker B, et al. CD22 is a negative regulator of B-cell receptor signaling[ J ]. Curr Biol, 1997, 7 : 133-143.
  • 4Browning J. B-cells move to centre stage: novel opportunities for auto-immune disease treatment [ J]. Nat Rev Drug Discov, 2006, 5:564-576.
  • 5Leandro M, Edwards JC, Cambridge G, et al. An open study of B lymphocyte depletion in systemic lupus erythematosus[ J]. Arthritis Rheum, 2002, 46:2673-2677.
  • 6Leandro M, Cambridge G, Edwards JC, et al. B-cell depletion in the treatment of patients with systemic lupus erythematosus : a longitudinal analysis of 24 patients [ J ]. Rheumatology ( Oxford ), 2005, 44 : 1542-1545.
  • 7Looney R, Anolik JH, Campbell D, et al. B cell deletion as a novel treatment for systemic lupus erythematosus: a phase Ⅰ/Ⅱ doseescalating trial of rituximab [ J ]. Arthritis Rheum, 2004, 50 : 258O-2589.
  • 8Tanaka Y, Yamamoto K, Takeuchi T, et al. A multicenter phase Ⅰ/Ⅱ trial of rituximab for refractory systemic lupus erythematosus [ J ]. Arthritis Rheum, 2006, 54 (suppl) : S258.
  • 9Dorner T, Kaufmann J, Wegener WA, et al. Initial clinical trial of epratuzumab ( humanized antiCD22 antibody) for immuno-therapy of systemic lupus erythematosus [ J ]. Arthritis Res Ther, 2006, 8 : R74.
  • 10Marks S, Patey S, Brogan PA, et al. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus [ J ]. Arthritis Rheum, 2005, 52:3168-3174.

同被引文献22

  • 1Ferndndez-Nebro A, Marsal S, Chatham W,et al. Sys- temic Lupus Erythematosus: Genomics, Mechanisms, and Therapies. Cli Dev Immunol, 2012,16 : 4-5.
  • 2Ramos-casals M, Sanz I, Bosch X, et al. B-cell-depleting therapy in systemic lupus erythematosus[J]. American J Med,2012,125(4) :327-336.
  • 3Arbuckle MR, McClain MT, Rubertone MV,et al. De- velopment of autoantibodies before the clinical onset of systemic lupus erythematosus[J]. N Engl J Med, 2003, 349(16):1 526-1 533.
  • 4Lo MS, Tsokos GC. Treatment of systemic lupus ery- thematosus:new advances in targeted therapy[J]. Ann N Y Acad Sci,2012,1 247:138-152.
  • 5Leandro MJ, Edwards JC, Cambridge G, et al. An open study of B lymphocyte depletion in systemic lupus ery- thematosus. Arthritis Rheum, 2002,46 (10) : 2 673- 2 677.
  • 6Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized,double- blind,phase II/III systemic lupus erythematosus evalu- ation of rituximab trial[J]. Arthritis Rheum, 2010,62 (1) :222-233.
  • 7Furie R,Looney J,Rovin B,et al. Efficacy and safety of rituximab in patients with proliferative lupus nephritis: results from the randomized, double-blind phase iii lu- nar study[J]. Ann Rheum Dis, 2010,69 : 549.
  • 8Ramos-Casals M,Diaz-Lagares C,Khamashta MA. Rit- uximab and lupus: good in real life, bad in controlled trials-comment on the article by Lu et al[J]. Arthritis Rheum, 2009,61(9):1 281-1 282.
  • 9Ramos-Casals M, Soto MJ, Cuadrado MJ, et al. Ritux- imab in systemic lupus erythematosus:a systematic re- view of off-label use in 188 cases[J]. Lupus, 2009,18 (9) :767-776.
  • 10Wallace DJ, Kalunian KC, Petri MA, et al. Epratuzumab demonstrates clinically meaningful improvements in pa- tients with moderate to severe systemic lupus erythe- matosus(SLE) : results from EMBLEM, a phase II b study[J]. Arthritis Rheum, 2010,69 (Suppl 3) : 558.

引证文献1

二级引证文献11

军医进修学院学报
2009年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部